Investigational Drug Information for Tivantinib
What is the drug development status for Tivantinib?
Tivantinib is an investigational drug.
There have been 28 clinical trials for Tivantinib.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 11th 2011.
The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are National Cancer Institute (NCI), Daiichi Sankyo Inc., and Daiichi Sankyo, Inc.
Summary for Tivantinib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,654 |
| WIPO Patent Applications | 442 |
| Japanese Patent Applications | 127 |
| Clinical Trial Progress | Phase 3 (2011-01-11) |
| Vendors | 60 |
Recent Clinical Trials for Tivantinib
| Title | Sponsor | Phase |
|---|---|---|
| TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES) | Istituto Oncologico Veneto IRCCS | Phase 2 |
| Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment | Medpace, Inc. | Phase 1 |
| Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment | Daiichi Sankyo Inc. | Phase 1 |
Clinical Trial Summary for Tivantinib
Top disease conditions for Tivantinib
Top clinical trial sponsors for Tivantinib
US Patents for Tivantinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Tivantinib Development Update, Patent Status, and Market Projection
Tivantibib, also known as ARQ 197, is an oral, selective c-MET inhibitor that failed to establish clinical benefit in late-stage hepatocellular carcinoma and non-small-cell lung cancer trials. The program has no FDA approval, no Orange Book listing, no commercial revenue base, and no active development program with a credible path to launch. The base-case market projection is zero through 2030 unless a sponsor revives the molecule for a narrowly defined biomarker-selected indication.
What is the current development status of tivantinib?
Tivantinib development is effectively discontinued.
ArQule developed tivantinib as a non-ATP-competitive inhibitor of the MET receptor tyrosine kinase. The program initially targeted hepatocellular carcinoma, non-small-cell lung cancer, colorectal cancer and other solid tumors. Daiichi Sankyo became a major development partner, but the principal late-stage studies failed to produce sufficient evidence for registration.
| Development area | Trial or program | Result | Current implication |
|---|---|---|---|
| Hepatocellular carcinoma | METIV-HCC, Phase III | Failed overall-survival primary endpoint | Registration path closed |
| Non-small-cell lung cancer | MARQUE, Phase III | Failed overall-survival endpoint | Broad NSCLC strategy abandoned |
| Non-small-cell lung cancer | ATTENTION, Phase III | Terminated after interim analysis for futility | Asian MET-selected strategy failed |
| Earlier solid-tumor studies | Phase I and Phase II trials | Mixed activity signals | Insufficient for continued development |
| Regulatory status | FDA | No approval | No marketed product |
| Commercial status | Global | No launch | No current revenue |
The METIV-HCC trial evaluated tivantinib against placebo in patients with MET-high advanced hepatocellular carcinoma who had received prior systemic treatment. The trial did not meet its overall-survival endpoint. The result eliminated the leading registration opportunity for the drug (Rimassa et al., 2018).
The MARQUE study evaluated tivantinib combined with erlotinib against erlotinib plus placebo in previously treated, nonsquamous NSCLC. It did not improve overall survival in the intent-to-treat population. The ATTENTION study, conducted primarily in Asian patients with MET-positive nonsquamous NSCLC, was stopped after an interim analysis found that the study was unlikely to meet its primary endpoint (Scagliotti et al., 2014).
When did tivantinib lose its exclusivity opportunity?
Tivantinib lost its practical exclusivity opportunity when the Phase III program failed, rather than when a patent formally expired.
The compound’s principal composition-of-matter patent family was filed in the mid-2000s. Public patent records associate tivantinib with ArQule patent families covering substituted quinoline compounds and their pharmaceutical uses. Depending on the specific U.S. patent, patent-term adjustments, terminal disclaimers and later claims, relevant protection was expected to run into the mid-2020s.
That patent timing no longer has material commercial significance because:
- Tivantinib was never approved by the FDA.
- No New Drug Application created an Orange Book reference product.
- No generic applicant has a conventional Abbreviated New Drug Application pathway tied to an approved tivantinib product.
- The clinical program did not establish a commercially viable indication before loss of effective market exclusivity.
What patents protect tivantinib?
The public record identifies patent families assigned primarily to ArQule and related entities that cover:
- Tivantinib and structurally related quinoline compounds.
- Pharmaceutical compositions containing the compounds.
- Inhibition of MET signaling.
- Use in cancers associated with MET activity or expression.
- Combination treatment with other anticancer agents.
Representative public patent records include U.S. patents associated with ArQule’s quinoline compound program, including U.S. Patent No. 7,598,249 and related continuation or divisional families. Patent scope differs by jurisdiction and by claim set. The existence of a composition patent did not create a viable product franchise because clinical failure preceded commercialization.
No active, FDA-linked Orange Book patent estate exists for tivantinib.
What is the FDA and Orange Book status of tivantinib?
Tivantinib has no FDA approval and is not listed in the FDA Orange Book as an approved drug product.
| FDA-related item | Status |
|---|---|
| New molecular entity approval | None |
| Approved indication | None |
| FDA label | None |
| Orange Book reference product | None |
| Orange Book-listed patents | None |
| Approved generic pathway | None |
| FDA exclusivity period | None |
The absence of FDA approval means tivantinib cannot be challenged through the standard Paragraph IV process against an approved reference listed drug. A company seeking to develop the molecule today would need to pursue a full NDA or another applicable regulatory pathway, supported by new clinical evidence.
Which companies developed or challenged tivantinib?
ArQule was the original developer and principal intellectual-property holder. Daiichi Sankyo entered into a development and commercialization relationship covering tivantinib in selected territories. The companies advanced the molecule into Phase III studies in HCC and NSCLC.
The major competitive challenge did not come from a generic company. It came from clinical competition and negative randomized trial results. Other MET-directed agents, including capmatinib, tepotinib, crizotinib and savolitinib, pursued more defined MET-driven populations or differentiated clinical settings.
Tivantinib also faced a mechanistic challenge. Later research questioned whether its antitumor activity was explained entirely by selective MET inhibition. That uncertainty weakened the rationale for continued development and reduced the likelihood that a sponsor would invest in a new large-scale confirmatory program.
What formulation and method-of-use patents protect tivantinib?
The patent estate included pharmaceutical composition and therapeutic-use claims, but no formulation has generated a commercial product or regulatory exclusivity.
Tivantinib was developed as an oral small-molecule tablet or capsule candidate. The formulation did not become a significant barrier to market entry because:
- The drug never reached approval.
- No approved dosage form established a reference product.
- No branded formulation franchise developed.
- No pediatric, orphan-drug or fixed-combination exclusivity was awarded.
Method-of-use claims directed to MET-positive HCC or NSCLC may have had commercial value only if the underlying clinical claims were validated. The negative Phase III outcomes substantially reduced the practical value of those use claims.
How strong is the tivantinib patent estate?
The patent estate is legally relevant but commercially weak.
| Patent-estate factor | Assessment |
|---|---|
| Composition-of-matter protection | Historically meaningful |
| Formulation protection | Limited commercial significance |
| Method-of-use protection | Undermined by failed trials |
| FDA regulatory exclusivity | None |
| Orange Book leverage | None |
| Biosimilar protection | Not applicable |
| Generic litigation risk | Low because no approved product exists |
| Freedom-to-operate risk | Potentially relevant for historical patent terms |
| Commercial value today | Low |
The strongest historical asset was likely the composition-of-matter protection. Its value declined as the patent term approached expiration and as the pivotal trials failed. A new sponsor would need to evaluate remaining patent term, claim breadth, terminal disclaimers, prosecution history and freedom-to-operate risk before investing in clinical redevelopment.
What patent litigation or settlement agreements affect tivantinib?
No major public Paragraph IV litigation or generic settlement is associated with tivantinib.
There was no approved reference product against which generic applicants could file ANDAs. The principal commercial dispute risk involved licensing rights, development obligations and control of the program rather than generic entry litigation.
No settlement agreement has created a recognized delayed-entry date for a generic tivantinib product.
What is the biosimilar risk for tivantinib?
Biosimilar risk is not applicable.
Tivantinib is a synthetic small molecule, not a biologic. If it were ever approved, generic-drug competition would arise under the Hatch-Waxman framework rather than through the biosimilar pathway. Since the drug has never been approved, there is no current abbreviated regulatory pathway linked to an FDA reference product.
How does tivantinib compare with competing MET inhibitors?
Tivantinib is commercially disadvantaged against approved or clinically validated MET inhibitors.
| Drug | Sponsor or commercial partner | MET strategy | Regulatory position | Competitive position |
|---|---|---|---|---|
| Tivantinib | ArQule, Daiichi Sankyo | Selective, non-ATP-competitive MET inhibition | Not approved | Discontinued |
| Capmatinib | Novartis | Selective MET inhibition | FDA-approved for MET exon 14-altered NSCLC | Validated biomarker strategy |
| Tepotinib | EMD Serono/Merck KGaA | Selective MET inhibition | FDA-approved for MET exon 14-altered NSCLC | Validated NSCLC indication |
| Crizotinib | Pfizer | ALK, ROS1 and MET activity | Approved in several molecular settings | Broader kinase profile |
| Savolitinib | AstraZeneca/Hutchmed | Selective MET inhibition | Regional approvals and development | Active biomarker-focused program |
Capmatinib and tepotinib benefited from a clearer molecular selection strategy centered on MET exon 14 skipping alterations. Tivantinib’s major studies relied heavily on MET protein expression or broader disease populations, which did not translate into reliable clinical benefit.
What is the market projection for tivantinib through 2030?
The base-case forecast is zero commercial sales through 2030.
| Scenario | Probability assessment | 2030 annual sales outlook | Required event |
|---|---|---|---|
| Base case | High | $0 | Program remains discontinued |
| Revival for a niche solid-tumor indication | Low | Below $50 million | New sponsor, new biomarker strategy and positive Phase II data |
| Successful redevelopment in MET-driven cancer | Very low | $50 million to $200 million | New pivotal trial and regulatory approval |
| Broad oncology relaunch | Remote | Above $200 million | Unlikely given prior Phase III failures and competition |
These are scenario estimates, not reported company guidance or an external consensus forecast. A relaunch would require a new clinical thesis, likely involving a narrowly selected molecular population. The sponsor would also need to establish whether tivantinib has differentiated activity from approved MET inhibitors on efficacy, safety, brain penetration, dosing convenience or combination use.
What revenue exposure does tivantinib create for current owners?
Tivantinib does not create material current revenue exposure for ArQule’s former shareholders, Daiichi Sankyo or another active commercial owner. The molecule has no marketed product, no recurring sales and no established reimbursement position.
Any residual value would come from:
- Out-licensing rights in jurisdictions with remaining patent term.
- Repurposing for a rare MET-driven tumor.
- Combination development with immunotherapy or another targeted agent.
- Use as a research tool in MET biology.
- Sale of historical clinical data or intellectual property.
Those options are speculative and materially weaker than the commercial position of approved MET inhibitors.
What generic launch risks exist for tivantinib?
A conventional generic launch is not the principal risk because no reference product exists. The more relevant risks for a hypothetical new sponsor are:
- Patent claims that remain enforceable in specific jurisdictions.
- Weak clinical differentiation from approved MET inhibitors.
- The need for new safety and efficacy studies.
- Uncertain predictive value of MET protein expression.
- Competitive pricing pressure from established targeted therapies.
- Limited physician adoption after failed Phase III trials.
- Potential regulatory concern about the mechanism and prior negative data.
A repurposed tivantinib product would face a long and expensive path before any generic or follow-on competition became relevant.
Key Takeaways
- Tivantinib is a discontinued oral c-MET inhibitor developed by ArQule with Daiichi Sankyo involvement.
- The METIV-HCC, MARQUE and ATTENTION programs failed to establish a registrational benefit.
- Tivantib has no FDA approval, Orange Book listing, approved indication or regulatory exclusivity.
- Historical composition-of-matter patents provided the main protection, but their commercial value declined after clinical failure and patent aging.
- No meaningful Paragraph IV litigation, generic settlement or biosimilar issue exists.
- The base-case 2030 market forecast is $0 in annual sales.
- A revival would require a new biomarker-defined indication and compelling differentiation from capmatinib, tepotinib and other MET-directed drugs.
FAQs
Could tivantinib still be approved for hepatocellular carcinoma?
Approval is highly unlikely without a new clinical program. The prior Phase III HCC study failed its overall-survival endpoint, and newer HCC treatments have increased the evidentiary and competitive burden.
Is tivantinib the same type of drug as capmatinib?
Both target MET, but they are different molecules. Capmatinib is an approved selective MET inhibitor for MET exon 14-altered NSCLC, while tivantinib was never approved.
Can a generic company file a Paragraph IV application for tivantinib?
Not in the conventional sense because there is no FDA-approved reference listed drug for tivantinib. A generic applicant would first need an approved reference product and applicable FDA regulatory pathway.
Does tivantinib have orphan-drug exclusivity?
No FDA orphan-drug exclusivity is associated with tivantinib. The molecule has no approved indication and no FDA marketing exclusivity.
What would make tivantinib commercially investable again?
A new sponsor would need reproducible activity in a molecularly defined population, a defensible patent or regulatory-exclusivity position, and clinical differentiation from approved MET inhibitors. Without those elements, the asset has limited strategic value.
References
-
ArQule, Inc. (2018). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
National Cancer Institute. (n.d.). ClinicalTrials.gov study record: METIV-HCC, tivantinib in patients with MET-high advanced hepatocellular carcinoma. U.S. National Library of Medicine.
-
National Cancer Institute. (n.d.). ClinicalTrials.gov study record: MARQUE, tivantinib plus erlotinib in nonsquamous non-small-cell lung cancer. U.S. National Library of Medicine.
-
National Cancer Institute. (n.d.). ClinicalTrials.gov study record: ATTENTION, tivantinib plus erlotinib in Asian patients with nonsquamous non-small-cell lung cancer. U.S. National Library of Medicine.
-
Rimassa, L., Assenat, E., Merle, P., Edeline, J., Conroy, G., Harris, W., et al. (2018). Tivantinib in patients with hepatocellular carcinoma and MET expression: A randomised, placebo-controlled, phase 2 trial. The Lancet Oncology, 19(5), 682-693.
-
Scagliotti, G., von Pawel, J., Novello, S., Ramlau, R., Puda, P., Moro-Sibilot, D., et al. (2014). Tivantinib in combination with erlotinib versus erlotinib alone for advanced nonsquamous non-small-cell lung cancer: A randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 15(3), 297-304.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
U.S. Patent No. 7,598,249. (2009). Quinoline compounds and methods of use. United States Patent and Trademark Office.
More… ↓
